Julie M. Vose, MD, MBA, discusses the use of CAR T-cell therapy in non-Hodgkin lymphoma.
Julie M. Vose, MD, MBA, Neumann M. and Mildred E. Harris Professor, chief, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, discusses the use of CAR T-cell therapy in non-Hodgkin lymphoma (NHL).
Currently, CAR T-cell therapies have FDA indications in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), as well as mantle cell lymphoma (MCL). However, this treatment modality is being evaluated for use in several subtypes of NHL in ongoing clinical trials, Vose says.
For example, trials are investigating CAR T-cell therapy in follicular lymphoma, chronic lymphocytic leukemia, and small lymphocytic lymphoma. Additionally, other products beyond those FDA approved are being tested in DLBCL and MCL, Vose concludes.